<p>Celldex Therapeutics, Inc. (NASDAQ:CLDX - 获取免费报告) 的股价在周四的午盘交易中创下了新的 52 周高点。该股最高交易价格为 29.40 美元，最后交易价格为 29.4580 美元，成交量为 176251 股。该股此前收盘价为 27.81 美元。</p>
<p>获取 <strong>Celldex Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>几位研究分析师最近对 CLDX 股票发表了看法。巴克莱将 Celldex Therapeutics 的目标价从 25.00 美元下调至 21.00 美元，并在 11 月 11 日的研究报告中对该公司给予了 “减持” 评级。HC Wainwright 将 Celldex Therapeutics 的目标价从 50.00 美元下调至 42.00 美元，并在 8 月 20 日的报告中对该公司给予了 “买入” 评级。Weiss Ratings 在 10 月 8 日的报告中重申了对 Celldex Therapeutics 的 “卖出（d-）” 评级。花旗将 Celldex Therapeutics 的目标价从 56.00 美元下调至 48.00 美元，并在 8 月 20 日的研究报告中对该公司给予了 “买入” 评级。最后，瑞穗证券在 10 月 21 日的报告中开始覆盖 Celldex Therapeutics 的股票。他们对该股给予了 “跑赢大盘” 评级，并设定了 48.00 美元的目标价。一位投资分析师对该股给予了强烈买入评级，七位给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，共识目标价为 43.80 美元。</p>
<p><strong>获取我们对 CLDX 的最新分析</strong></p>
<h2>Celldex Therapeutics 上涨 5.2%</h2>
<p>该股的 50 日移动平均价格为 25.96 美元，200 日移动平均价格为 23.45 美元。该公司的市值为 19.4 亿美元，市盈率为-8.68，贝塔值为 1.13。</p>
<p>Celldex Therapeutics (NASDAQ:CLDX - 获取免费报告) 最近于 11 月 10 日发布了其财报。这家生物制药公司报告本季度每股收益为 (-1.01) 美元，低于分析师一致预期的 (-0.88) 美元，差距为 (-0.13) 美元。Celldex Therapeutics 的股本回报率为-33.22%，净利润率为-3446.88%。卖方分析师预计 Celldex Therapeutics, Inc.将在本财年发布每股收益-2.48 美元。</p>
<h2>Celldex Therapeutics 的内部交易</h2>
<p>在其他 Celldex Therapeutics 的新闻中，内部人士 Richard M. Wright 于 11 月 13 日出售了 49,298 股 Celldex Therapeutics 的股票。该股票以平均价格 24.00 美元出售，总交易额为 1,183,152.00 美元。交易后，该内部人士持有 20,833 股公司股票，价值 499,992 美元。此次交易使其持股减少了 70.29%。该交易已在与 SEC 的法律文件中披露，相关文件可通过此超链接获取。公司内部人士持有公司 4.40% 的股份。</p>
<h2>Celldex Therapeutics 的机构交易</h2>
<p>几位大型投资者最近增加或减少了在 CLDX 的持股。Handelsbanken Fonder AB 在第二季度将其在 Celldex Therapeutics 的持股增加了 2.4%。Handelsbanken Fonder AB 目前持有 21,600 股该生物制药公司的股票，价值 440,000 美元，此前在上个季度购买了 500 股。拉塞尔投资集团在第二季度将其在 Celldex Therapeutics 的持股增加了 27.6%。拉塞尔投资集团目前持有 2,315 股该生物制药公司的股票，价值 47,000 美元，此前在上个季度增持了 501 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Celldex Therapeutics 的持股增加了 1.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 43,451 股该生物制药公司的股票，价值 798,000 美元，此前在该期间增持了 680 股。AlphaQuest LLC 在第二季度将其在 Celldex Therapeutics 的持股增加了 7.0%。AlphaQuest LLC 目前持有 12,956 股该生物制药公司的股票，价值 264,000 美元，此前在该期间增持了 844 股。最后，Nisa Investment Advisors LLC 在第二季度将其在 Celldex Therapeutics 的持股增加了 171.7%。Nisa Investment Advisors LLC 目前持有 1,394 股该生物制药公司的股票，价值 28,000 美元，此前在上个季度增持了 881 股。</p>
<h2>Celldex Therapeutics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Celldex Therapeutics, Inc.是一家生物制药公司，专注于开发用于治疗各种疾病的治疗性单克隆抗体和双特异性抗体。其药物候选者包括用于治疗炎症、过敏、自身免疫及其他严重疾病的抗体基础治疗。</p>
<h2>推荐阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Celldex Therapeutics</li>
<li>FAANG 股票是什么，它们是好的投资吗？</li>
<li>Wolfspeed 刚获得 6.98 亿美元的救助——这就是为什么这改变了一切</li>
<li>10 只最佳航空公司股票推荐</li>
<li>Uber 在达拉斯推出机器人出租车后获得华尔街最高评级</li>
<li>股票交易：RSI 及其用途</li>
<li>投资者对 Box 的看法完全错误——这次由 AI 驱动的反弹刚刚证明了这一点</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Celldex Therapeutics 吗？</h2>
<p>在你考虑 Celldex Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而塞德斯医疗并不在名单上。</p>
<p>虽然塞德斯医疗目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

塞德斯医疗

<p>塞德斯医疗 (NASDAQ:CLDX) 达到了新的 52 周高点，交易价格为 29.4580 美元。分析师的评级意见不一，普遍目标价为 43.80 美元。该公司报告了季度亏损，未能达到预期。内部人士 Richard M. Wright 出售了股份，减少了 70.29% 的持股比例。机构投资者调整了在该公司的持股。塞德斯医疗开发用于治疗各种疾病的治疗性抗体</p>

<p>Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $29.40 and last traded at $29.4580, with a volume of 176251 shares changing hands. The stock had previously closed at $27.81.</p>
<div class="lb-trans"><p>Celldex Therapeutics, Inc. (NASDAQ:CLDX - 获取免费报告) 的股价在周四的午盘交易中创下了新的 52 周高点。该股最高交易价格为 29.40 美元，最后交易价格为 29.4580 美元，成交量为 176251 股。该股此前收盘价为 27.81 美元。</p>
</div><p>Get <strong>Celldex Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Celldex Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several research analysts have recently weighed in on CLDX shares. Barclays decreased their target price on shares of Celldex Therapeutics from $25.00 to $21.00 and set an &#34;underweight&#34; rating for the company in a research note on Tuesday, November 11th. HC Wainwright reduced their price target on Celldex Therapeutics from $50.00 to $42.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, August 20th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Celldex Therapeutics in a report on Wednesday, October 8th. Citigroup decreased their price target on shares of Celldex Therapeutics from $56.00 to $48.00 and set a &#34;buy&#34; rating for the company in a research report on Wednesday, August 20th. Finally, Mizuho assumed coverage on shares of Celldex Therapeutics in a report on Tuesday, October 21st. They issued an &#34;outperform&#34; rating and a $48.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $43.80.</p>
<div class="lb-trans"><p>几位研究分析师最近对 CLDX 股票发表了看法。巴克莱将 Celldex Therapeutics 的目标价从 25.00 美元下调至 21.00 美元，并在 11 月 11 日的研究报告中对该公司给予了 “减持” 评级。HC Wainwright 将 Celldex Therapeutics 的目标价从 50.00 美元下调至 42.00 美元，并在 8 月 20 日的报告中对该公司给予了 “买入” 评级。Weiss Ratings 在 10 月 8 日的报告中重申了对 Celldex Therapeutics 的 “卖出（d-）” 评级。花旗将 Celldex Therapeutics 的目标价从 56.00 美元下调至 48.00 美元，并在 8 月 20 日的研究报告中对该公司给予了 “买入” 评级。最后，瑞穗证券在 10 月 21 日的报告中开始覆盖 Celldex Therapeutics 的股票。他们对该股给予了 “跑赢大盘” 评级，并设定了 48.00 美元的目标价。一位投资分析师对该股给予了强烈买入评级，七位给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，共识目标价为 43.80 美元。</p>
</div><p><strong>Get Our Latest Analysis on CLDX</strong></p>
<div class="lb-trans"><p><strong>获取我们对 CLDX 的最新分析</strong></p>
</div><h2>Celldex Therapeutics Trading Up 5.2%</h2>
<div class="lb-trans"><h2>Celldex Therapeutics 上涨 5.2%</h2>
</div><p>The stock's 50-day moving average price is $25.96 and its 200-day moving average price is $23.45. The company has a market capitalization of $1.94 billion, a P/E ratio of -8.68 and a beta of 1.13.</p>
<div class="lb-trans"><p>该股的 50 日移动平均价格为 25.96 美元，200 日移动平均价格为 23.45 美元。该公司的市值为 19.4 亿美元，市盈率为-8.68，贝塔值为 1.13。</p>
</div><p>Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 33.22% and a negative net margin of 3,446.88%. Sell-side analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Celldex Therapeutics (NASDAQ:CLDX - 获取免费报告) 最近于 11 月 10 日发布了其财报。这家生物制药公司报告本季度每股收益为 (-1.01) 美元，低于分析师一致预期的 (-0.88) 美元，差距为 (-0.13) 美元。Celldex Therapeutics 的股本回报率为-33.22%，净利润率为-3446.88%。卖方分析师预计 Celldex Therapeutics, Inc.将在本财年发布每股收益-2.48 美元。</p>
</div><h2>Insider Transactions at Celldex Therapeutics</h2>
<div class="lb-trans"><h2>Celldex Therapeutics 的内部交易</h2>
</div><p>In other Celldex Therapeutics news, insider Richard M. Wright sold 49,298 shares of Celldex Therapeutics stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the transaction, the insider owned 20,833 shares of the company's stock, valued at $499,992. The trade was a 70.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 4.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Celldex Therapeutics 的新闻中，内部人士 Richard M. Wright 于 11 月 13 日出售了 49,298 股 Celldex Therapeutics 的股票。该股票以平均价格 24.00 美元出售，总交易额为 1,183,152.00 美元。交易后，该内部人士持有 20,833 股公司股票，价值 499,992 美元。此次交易使其持股减少了 70.29%。该交易已在与 SEC 的法律文件中披露，相关文件可通过此超链接获取。公司内部人士持有公司 4.40% 的股份。</p>
</div><h2>Institutional Trading of Celldex Therapeutics</h2>
<div class="lb-trans"><h2>Celldex Therapeutics 的机构交易</h2>
</div><p>Several large investors have recently added to or reduced their stakes in CLDX. Handelsbanken Fonder AB grew its position in Celldex Therapeutics by 2.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 21,600 shares of the biopharmaceutical company's stock worth $440,000 after purchasing an additional 500 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 501 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Celldex Therapeutics by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company's stock worth $798,000 after acquiring an additional 680 shares during the period. AlphaQuest LLC increased its position in shares of Celldex Therapeutics by 7.0% during the second quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company's stock valued at $264,000 after purchasing an additional 844 shares during the period. Finally, Nisa Investment Advisors LLC raised its stake in shares of Celldex Therapeutics by 171.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 881 shares in the last quarter.</p>
<div class="lb-trans"><p>几位大型投资者最近增加或减少了在 CLDX 的持股。Handelsbanken Fonder AB 在第二季度将其在 Celldex Therapeutics 的持股增加了 2.4%。Handelsbanken Fonder AB 目前持有 21,600 股该生物制药公司的股票，价值 440,000 美元，此前在上个季度购买了 500 股。拉塞尔投资集团在第二季度将其在 Celldex Therapeutics 的持股增加了 27.6%。拉塞尔投资集团目前持有 2,315 股该生物制药公司的股票，价值 47,000 美元，此前在上个季度增持了 501 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Celldex Therapeutics 的持股增加了 1.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 43,451 股该生物制药公司的股票，价值 798,000 美元，此前在该期间增持了 680 股。AlphaQuest LLC 在第二季度将其在 Celldex Therapeutics 的持股增加了 7.0%。AlphaQuest LLC 目前持有 12,956 股该生物制药公司的股票，价值 264,000 美元，此前在该期间增持了 844 股。最后，Nisa Investment Advisors LLC 在第二季度将其在 Celldex Therapeutics 的持股增加了 171.7%。Nisa Investment Advisors LLC 目前持有 1,394 股该生物制药公司的股票，价值 28,000 美元，此前在上个季度增持了 881 股。</p>
</div><h2>Celldex Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Celldex Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.</p>
<div class="lb-trans"><p>Celldex Therapeutics, Inc.是一家生物制药公司，专注于开发用于治疗各种疾病的治疗性单克隆抗体和双特异性抗体。其药物候选者包括用于治疗炎症、过敏、自身免疫及其他严重疾病的抗体基础治疗。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐阅读</h2>
</div><ul>
<li>Five stocks we like better than Celldex Therapeutics</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Wolfspeed Just Got a $698 Million Lifeline—Here’s Why That Changes Everything</li>
<li>10 Best Airline Stocks to Buy</li>
<li>Uber Gets a Street-High Upgrade as Robotaxis Roll Out in Dallas</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Investors Were Dead Wrong About Box—This AI-Driven Comeback Just Proved It</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Celldex Therapeutics</li>
<li>FAANG 股票是什么，它们是好的投资吗？</li>
<li>Wolfspeed 刚获得 6.98 亿美元的救助——这就是为什么这改变了一切</li>
<li>10 只最佳航空公司股票推荐</li>
<li>Uber 在达拉斯推出机器人出租车后获得华尔街最高评级</li>
<li>股票交易：RSI 及其用途</li>
<li>投资者对 Box 的看法完全错误——这次由 AI 驱动的反弹刚刚证明了这一点</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Celldex Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Celldex Therapeutics 吗？</h2>
</div><p>Before you consider Celldex Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Celldex Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而塞德斯医疗并不在名单上。</p>
</div><p>While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然塞德斯医疗目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

塞德斯医疗（NASDAQ:CLDX）创下 12 个月新高 - 原因如下